The 340B Drug Pricing Program was designed to help vulnerable patients access medications at safety-net facilities. Since the program was created in 1992, manufacturers have provided tens of billions of dollars each year in steep discounts on outpatient medicines to safety-net clinics and qualifying hospitals expecting those entities would use the savings to ensure vulnerable patients have access to needed medicines. But the 340B program has strayed far from its safety-net purpose. Instead, it creates incentives that drive up health care costs and it boosts the bottom lines of hospitals and for-profit pharmacies instead of helping patients.